🇺🇸 FDA
Patent

US 10624850

Emulsion formulations of an NK-1 receptor antagonist and uses thereof

granted A61KA61K31/43A61K31/435

Quick answer

US patent 10624850 (Emulsion formulations of an NK-1 receptor antagonist and uses thereof) held by Heron Therapeutics, Inc. expires Mon Apr 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Heron Therapeutics, Inc.
Grant date
Tue Apr 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/43, A61K31/435, A61K31/496, A61K31/5377